IBJNews

Lilly, Bristol-Myers approved to market wider Erbitux use

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors.

The Food and Drug Administration cleared the medicine for use with chemotherapy to treat patients with head and neck cancer that has spread, the agency said Monday in a prepared statement.

Erbitux, made by Indianapolis-based Lilly’s ImClone unit, already is approved in the U.S. to treat colon cancer and head and neck tumors that haven’t spread.

Bristol-Myers, based in New York, generated $662 million in 2010 sales from the drug, while Lilly’s manufacturing revenue was $71.9 million. Lilly acquired ImClone in 2008.

“Erbitux’s ability to extend the lives of patients with head and neck cancers is an important tool for oncologists who often rely on a multitreatment approach for patients,” Richard Pazdur, director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research, said in the prepared statement.

Bristol-Myers Squibb shares rose less than 1 percent, to $31.39 each at Monday's close. Lilly shares advanced 1.1 percent, to $38.35.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
thisissue1-092914.jpg 092914

Subscribe to IBJ
ADVERTISEMENT